Vaezi M F, Richter J E
Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Am J Med. 2001 Dec 3;111 Suppl 8A:160S-168S. doi: 10.1016/s0002-9343(01)00827-0.
The role of duodenogastroesophageal reflux (DGER), once erroneously termed "bile reflux," in causing esophageal mucosal damage has been an area of interest in both animal and human studies. However, because of the lack of appropriate techniques to accurately measure DGER, extrapolation of findings from animal studies to humans has been difficult to make. The recent advent of the Bilitec system (Metronics Instruments, Minneapolis, MN), an ambulatory bilirubin monitoring device, is increasing our knowledge of the specific role of DGER in esophageal diseases. Studies suggest that DGER without acid reflux may result in symptoms, but unless acid reflux is present simultaneously, it does not cause esophagitis. Therefore, therapies should aim at reducing both DGER and acid reflux. Studies show that this may be accomplished by antireflux surgery or the use of proton pump inhibitors, which by reducing gastric volume, decrease the damaging potential of both acid and DGER.
十二指肠-胃食管反流(DGER)曾被错误地称为“胆汁反流”,其在导致食管黏膜损伤方面的作用一直是动物和人体研究的关注领域。然而,由于缺乏准确测量DGER的合适技术,很难将动物研究的结果外推至人类。动态胆红素监测设备Bilitec系统(美敦力仪器公司,明尼阿波利斯,明尼苏达州)的近期问世,正在增加我们对DGER在食管疾病中具体作用的认识。研究表明,无酸反流的DGER可能导致症状,但除非同时存在酸反流,否则不会引起食管炎。因此,治疗应旨在减少DGER和酸反流。研究表明,这可通过抗反流手术或使用质子泵抑制剂来实现,质子泵抑制剂通过减少胃容量,降低酸和DGER的损伤潜能。